Objective:To investigate the efficacy of Aidi injection in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer(NSCLC). Methods: Eighty patients with advanced NSCLC were randomly divided into control group (n=42) and observation group(n = 38) from Jun 2009 to Jan 2011. Patients in the control group were given gemcitabine plus cisplatin(GP) chemotherapy alone, while patients in the observation group were given GP chemotherapy plus Aidi injection. Clinical efficacy, including therapeutic efficiency, quality of life, adverse reaction and immune function were compared between the two groups after three cycles of chemotherapy. Results: Therapeutic efficiency of observation group and control group were 50.0% and 42. 8%, and there were no statistically significant difference between them(P＞ 05). Improvement rates of Karnofsky performance status scale (KPS) score in observation group and control group were 36. 84% and 21. 43% , and there were statistically significant difference between them(P<0. 05). Adverse reaction rates in observation group were lower than those in control group, there were statistically significant difference between them(P<0. 05). Immune indexes in observation group after chemotherapy improved and those in control group dropped, there were statistically significant differences between them(P<0. 05). Conclusions: Therapy of Aidi injection combined with gemcitabine plus cisplatin can not only improve the life quality of NSCLC patients, but also lower the rates of adverse reaction and protect immune function.%目的:探讨GP方案(吉西他滨+顺铂)联合艾迪注射液治疗晚期非小细胞肺癌(NSCLC)的疗效.方法:回顾分析80例晚期NSCLC患者的临床资料.其中42例采用GP方案治疗,为对照组；38例采用GP方案联合艾迪注射液治疗,为观察组.3个疗程后比较患者的治疗有效率、生活质量、化疗不良反应以及机体免疫功能.结果:观察组及对照组的治疗有效率分别为50％和42.8％,差异无统计学意义(P＞0.05)；生活质量Karnofsky评分(KPS)比较,观察组及对照组改善率分别为36.84％和21.43％,差异有统计学意义(P＜0.05)；观察组化疗不良反应的发生率低于对照组,差异有统计学意义(P＜0.05)；观察组化疗后免疫指标有较大的提高,而对照组则有明显下降,差异有统计学意义(P＜0.05).结论:GP方案联合艾迪注射液治疗晚期NSCLC,可改善患者生活质量,减轻化疗不良反应,保护机体的免疫功能.
展开▼
